Press release
Carbapenem-resistant Enterobacteriaceae Testing Market to Partake Significant Development During 2018 – 2028
Enterobacteriaceae are a family of germs that most commonly live in a person’s bowel without causing any disease. Carbapenems are strong antibiotics that are commonly used to treat serious infections. A few enterobacteriaceaea have gained resistance to these antibiotics. These are called Carbapenem-resistant Enterobacteriaceae. Carbapenem-resistant Enterobacteriaceae testing is considered to be a gram-negative pathogen testing. Common gram-negative pathogens include Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, Enterobacter aerogenes and Acinetobacterbaumannii. These gram-negative pathogens can be mediated and treated by transferable carbapenemase-encoding genes. A few infections caused by carbapenem-resistant Enterobacteriaceae outside the bowel include wound infection, urinary tract infection (UTI) and pneumonia. People prone to Carbapenem-resistant enterobacteriaceae include people admitted to hospitals or other healthcare settings. According to The Centers for Disease Control and Prevention (CDC), around 2 million people are infected by antibiotic-resistant organisms every year, which further leads to approximately 23,000 deaths annually. The mortality rates are also high, ranging from 40%-50%. Two major factors responsible for this kind of infection are use of mechanical ventilation and use of beta-lactam antibiotics. Beta-lactam antibiotics include Cephalosporins, Penicillins, monobactams and Carbapenems. Carbapenem-resistant enterobacteriaceae testing includes disc diffusion or automated systems, selective agar Carbapenem-resistant enterobacteriaceae testing, minimal inhibitory concentration (MIC) for Carbapenem-resistant enterobacteriaceae testing, synergy Carbapenem-resistant enterobacteriaceae testing, modified Hodge tests, whole genome sequencing, spectrometrics and various other molecular methods.Request to Sample report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=2268
Carbapenem-resistant Enterobacteriaceae Testing Market: Drivers
People admitted to any healthcare setting for medical care are more prone to infection and to go for Carbapenem-resistant enterobacteriaceae testing than healthy people. Increase in the number of people requiring inpatient medical assistance, growing number of healthcare facilities, increased number of complex surgeries, multiple use of several antibiotics and rise in use of medical devices in the body, such as urinary catheters, intravenous catheters and ventilators, are few of the major factors responsible for growth in the Carbapenem-resistant enterobacteriaceae testing market. Growing awareness about prevention of Carbapenem resistance and increased efforts by governments through the implementation of infection prevention and control measures might hinder the growth of the Carbapenem-resistant enterobacteriaceae testing market during the forecast period.
Carbapenem-resistant Enterobacteriaceae Testing Market: Segmentation
Based on test type, the global Carbapenem-resistant Enterobacteriaceae Testing Market is segmented as:
Modified Hodge Carbapenem-resistant Enterobacteriaceae Testing
Minimal inhibitory concentration Carbapenem-resistant Enterobacteriaceae Testing
Other types of Carbapenem-resistant Enterobacteriaceae Testing
Based on end users, the global Carbapenem-resistant Enterobacteriaceae Testing Market is segmented as:
Hospitals
Ambulatory Surgical Centers
Intensive Care Units
Clinics
Nursing Homes
Long Term Acute Care Centers
Others
Based on geography, the global Carbapenem-resistant Enterobacteriaceae Testing Market is segmented as:
North America
Latin America
Europe
CIS & Russia
Japan
APEJ
Middle East & Africa
Request to View TOC @ https://www.factmr.com/connectus/sample?flag=T&rep_id=2268
Carbapenem-resistant Enterobacteriaceae Testing Market: Overview
In Carbapenem-resistant Enterobacteriaceae Testing, Modified Hodge tests are anticipated to be one of the leading test types for Carbapenem-resistant enterobacteriaceae testing because of high accuracy of test results. These tests are easy to perform and can be performed in a routine laboratory, which makes them more feasible and thus, one of the leading test types in Carbapenem-resistant enterobacteriaceae testing market. Molecular testing detects the resistance mechanism whereas phenotypic tests detect the in-vitro activity of carbapenemase enzyme. Healthcare settings, such as nursing homes and acute care centers, where constant medical care is required for a longer duration of time are more prone to CRE and thus, the demand for Carbapenem-resistant enterobacteriaceae testing is higher in these settings.
Carbapenem-resistant Enterobacteriaceae Testing Market: Regional Outlook
According to The Centers for Disease Control and Prevention (CDC), by 2013 Carbapenem-resistant enterobacteriaceae was found in almost 42 states. CDC also stated that enterobacteriaceae proportion of Carbapenem-resistance has consistently increased and has increased four-fold in the past ten years. During the early 2000s, CRE was rare in the North America region. However, the breakout of CRE in the northeast spread through the US, thereby boosting the market for Carbapenem-resistant enterobacteriaceae testing in the region. The Asia-pacific market for Carbapenem-resistant enterobacteriaceae testing is also expected to expand during the forecast period because of detection of different classes of carbapenemase.
Carbapenem-resistant Enterobacteriaceae Testing Market: Key Players
Some of major participants operating in the Carbapenem-resistant Enterobacteriaceae Testing market are TBA, SolGent Co., Ltd., ELITechGroup, ALIFAX S.r.l. and bioMérieux, Inc.
Get Full Report Access @ https://www.factmr.com/report/2268/carbapenem-resistant-enterobacteriaceae-testing-market
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Carbapenem-resistant Enterobacteriaceae Testing Market to Partake Significant Development During 2018 – 2028 here
News-ID: 1823384 • Views: …
More Releases from Fact.MR

Neonatal Monitoring Equipment Market Forecasted to Grow at 6.4% CAGR, Hitting US …
The neonatal monitoring equipment market is projected to be valued at USD 980 million in 2025. It is expected to grow at a CAGR of 6.4%, reaching USD 1,826 million by 2035.
The neonatal monitoring equipment market is an essential segment of the healthcare industry, focusing on tools and devices designed to monitor the vital signs and health of newborns, especially those who are premature or critically ill. These devices are…

Cardiovascular Disease Monitoring and Diagnostic Devices Market Set to Reach USD …
The cardiovascular disease monitoring and diagnostic devices market is expected to be valued at USD 32.6 billion in 2025. According to research by Fact.MR, the market is projected to grow at a CAGR of 6.1%, reaching USD 58.8 billion by 2035.
The cardiovascular disease (CVD) monitoring and diagnostic devices market encompasses a wide range of products used to monitor, diagnose, and manage cardiovascular diseases, one of the leading causes of morbidity…

Bactericides Market Set to Reach USD 16.4 Billion by 2035, Growing at 5.2% CAGR
The bactericides market is projected to reach USD 9.8 billion by 2025. According to Fact.MR, the industry is expected to grow at a CAGR of 5.2%, reaching a value of USD 16.4 billion by 2035. This growth is largely fueled by rising concerns over crop yield security and the increasing prevalence of bacterial infections in high-value crops.
The bactericides market plays a critical role in modern agriculture, healthcare, and industrial sectors…

Urinary Tract Infection Treatment Market to Expand at 5.6% CAGR, Surpassing USD …
The urinary tract infection treatment market is expected to grow to USD 12,865 million by 2025. According to Fact.MR, the market is anticipated to expand at a CAGR of 5.6%, reaching USD 22,174 million by 2035.
The urinary tract infection (UTI) treatment market focuses on the range of products and therapies designed to combat infections that affect the urinary system, including the bladder, kidneys, and urethra. UTIs are among the most…
More Releases for Carbapenem
North America Carbapenem-Based Antibiotics Market Growth Boosting Factors, Chall …
The North America carbapenem-based antibiotics market is expected to reach US$ 1,713.21 million by 2028 from US$ 1,244.59 million in 2021; it is estimated to grow at a CAGR of 4.7% from 2021-2028.
The latest North America Carbapenem-Based Antibiotics Market study offers an all-inclusive analysis of the major strategies, corporate models, and market shares of the most noticeable players in this market. The study offers a thorough analysis of the key…
North America Carbapenem-Based Antibiotics Market Size and Growth Opportunities …
The North America carbapenem-based antibiotics market is expected to reach US$ 1,713.21 million by 2028 from US$ 1,244.59 million in 2021; it is estimated to grow at a CAGR of 4.7% from 2021-2028.
The market's growth is attributed to driving factors such as rising prevalence of bacterial infections and increasing development of generic drugs. However, the tedious and expensive process of the development of antibiotics is expected to restrain the market's…
2021 Carbapenem Market Report- by Leading Manufacturers, its Application and Typ …
Carbapenem Market report also provides supply and demand trends along with an overview of the parent market. Moreover, Carbapenem Market report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current Carbapenem Market forces, and the significant interventions of governments.
Get FREE PDF Sample of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5023854
By Company
- Pfizer
- Savior Lifetec
- Sun Pharmaceutical Industries
- Kopran
-…
Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections i …
Enterobacteriaceae are a family of germs that most commonly live in a person’s bowel without causing any disease. Carbapenems are strong antibiotics that are commonly used to treat serious infections. A few enterobacteriaceaea have gained resistance to these antibiotics. These are called Carbapenem-resistant Enterobacteriaceae. Carbapenem-resistant Enterobacteriaceae testing is considered to be a gram-negative pathogen testing. Common gram-negative pathogens include Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, Enterobacter aerogenes and Acinetobacterbaumannii. These…
Carbapenem-based Antibiotics Market to Exhibit 7% CAGR, with Sales of Tebipenem …
Incidence of bacterial infections with multidrug resistance is increasing rapidly, generating the need for novel, broad-spectrum carbapenem-based antibiotics for the treatment of various bacterial infections. Broad-spectrum carbapenem-based antibiotics such as tebipenem (Spero Therapeutics Inc.) and sulopenem (Iterum Therapeutics Inc.) are at late stage clinical development with expected launch of both in 2020 - 2021.
Multidrug resistance to currently marketed carbapenem-based antibiotics is largely prevalent in the world. Also, expiry of…
Carbapenem-resistant Enterobacteriaceae Testing Market Analysis, Segments, Growt …
Enterobacteriaceae are a family of germs that most commonly live in a person’s bowel without causing any disease. Carbapenems are strong antibiotics that are commonly used to treat serious infections. A few enterobacteriaceaea have gained resistance to these antibiotics. These are called Carbapenem-resistant Enterobacteriaceae. Carbapenem-resistant Enterobacteriaceae testing is considered to be a gram-negative pathogen testing. Common gram-negative pathogens include Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, Enterobacter aerogenes and Acinetobacterbaumannii.
These gram-negative…